Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.

The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Savara Inc. is headquartered in Langhorne, Pennsylvania.

Savara Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	37
CEO	Matthew Pauls J.D., M.B.A.

Contact Details

Address: 6836 Bee Cave Road, Building 3, Suite 201 Austin, Texas 78746 United States
Phone	51285113796
Website	savarapharma.com

Stock Details

Ticker Symbol	SVRA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001160308
CUSIP Number	805111101
ISIN Number	US8051111016
Employer ID	84-1318182
SIC Code	2834

Key Executives

Name	Position
Matthew Pauls J.D., M.B.A.	Chairman and Chief Executive Officer
David L. Lowrance CPA	Chief Financial Officer, Chief Administrative Officer and Secretary
Dr. Raymond Dennis Pratt FACP, M.D.	Chief Medical Officer
Robert Lutz M.B.A.	Chief Operating Officer
Kate McCabe J.D.	Senior Vice President and General Counsel
Anne Erickson	Chief Business Officer
Brian Maurer	Head of Clinical Operations
Charles LaPree	Senior Vice President of Global Regulatory Affairs and Quality Assurance
Dr. Peter Clarke Ph.D.	Executive Vice President of Global Technical Operations
Scott L. Wilhoit	Executive Vice President of Global Commercial

Latest SEC Filings

Date	Type	Title
Jul 8, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Jun 28, 2024	8-K	Current Report
Jun 28, 2024	424B5	Filing
Jun 26, 2024	8-K	Current Report
Jun 10, 2024	8-K/A	[Amend] Current report
Jun 7, 2024	8-K	Current Report
May 21, 2024	EFFECT	Notice of Effectiveness
May 14, 2024	UPLOAD	Filing
May 9, 2024	S-3	Registration statement under Securities Act of 1933
May 9, 2024	10-Q	Quarterly Report

View All SEC Filings